- Home
- DFIN vs SPRY Comparison
DFIN vs SPRY Comparison
Compare DFIN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- SPRY
- Stock Information
- Founded
- DFIN 1983
- SPRY 2015
- Country
- DFIN United States
- SPRY United States
- Employees
- DFIN N/A
- SPRY N/A
- Industry
- DFIN Other Consumer Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- SPRY Health Care
- Exchange
- DFIN Nasdaq
- SPRY Nasdaq
- Market Cap
- DFIN 1.4B
- SPRY 1.2B
- IPO Year
- DFIN N/A
- SPRY N/A
- Fundamental
- Price
- DFIN $44.81
- SPRY $13.05
- Analyst Decision
- DFIN Strong Buy
- SPRY Strong Buy
- Analyst Count
- DFIN 3
- SPRY 4
- Target Price
- DFIN $71.33
- SPRY $28.75
- AVG Volume (30 Days)
- DFIN 387.2K
- SPRY 2.0M
- Earning Date
- DFIN 04-30-2025
- SPRY 03-20-2025
- Dividend Yield
- DFIN N/A
- SPRY N/A
- EPS Growth
- DFIN 13.76
- SPRY N/A
- EPS
- DFIN 3.06
- SPRY 0.08
- Revenue
- DFIN $781,900,000.00
- SPRY $89,149,000.00
- Revenue This Year
- DFIN $4.59
- SPRY $41.49
- Revenue Next Year
- DFIN $4.40
- SPRY $80.23
- P/E Ratio
- DFIN $14.59
- SPRY $162.38
- Revenue Growth
- DFIN N/A
- SPRY 297063.34
- 52 Week Low
- DFIN $41.76
- SPRY $7.55
- 52 Week High
- DFIN $71.01
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- DFIN 38.83
- SPRY 57.72
- Support Level
- DFIN $43.20
- SPRY $11.85
- Resistance Level
- DFIN $46.51
- SPRY $13.22
- Average True Range (ATR)
- DFIN 1.39
- SPRY 0.93
- MACD
- DFIN 0.57
- SPRY 0.07
- Stochastic Oscillator
- DFIN 64.28
- SPRY 49.29
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.